Abbvie (ABBV) PT Raised to $140 at JPMorgan
Get Alerts ABBV Hot Sheet
Price: $266.28 +0.73%
Rating Summary:
28 Buy, 10 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 53
Rating Summary:
28 Buy, 10 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 53
Join SI Premium – FREE
JPMorgan analyst Chris Schott raised the price target on Abbvie (NYSE: ABBV) to $140.00 (from $135.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Vertex (VRTX) PT Raised to $615 at UBS
- FDA approves AbbVie's tavapadon for Parkinson's disease
- U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share